A fascinating new study observing the effects of the psychedelic drug DMT - or dimethyltryptamine - on people who have already tried two other forms of treatment for depression has recorded “significant and lasting reductions” in depressive symptoms after a single dose.

This study, led by David Erritzoe from the Imperial College in London, shows the potential DMT could bring to the burgeoning psychedelic assisted therapy space. In 2023, The Therapeutic Goods Administration approved authorised psychiatrists to prescribe psilocybin for depression, and MDMA for PTSD. 

Guest: David Erritzoe, psychiatrist and neuroscientist at the Imperial College London, and the lead investigator of this study.